Month: March 2025

Danish Ship Finance issues new fixed rate non-callable bullet bond (SCB) with maturity date 25 March 2031. In connection with the opening of new ISINs under the Danish Ship Finance A/S base prospectus dated 9 July 2024, as supplemented by supplement no. 1 dated 26 August 2024, and further supplemented by supplement no. 2 dated 27 February 2025, Danish Ship Finance issues new Final Bond Terms.  The Final Bond Terms are stated below.  The Danish Ship Finance A/S Base Prospectus dated 9 July 2024, including the supplements there to and the relevant Final Bond Terms are available for download on Danish Ship Finance A/S’ website at http://www.shipfinance.dk/investor-relations/.  ISIN  Capital Centre  Currency  Opening date  Maturity DK0004134020  Capital Centre A  EUR  25 March 2025  25 March 2031 Questions may...

MACAU, March 21, 2025 (GLOBE NEWSWIRE) — Studio City International Holdings Limited (NYSE: MSC) (“Studio City” or the “Company”), a world-class integrated resort located in Cotai, Macau, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The annual report can be accessed under the Annual Reports section on the Company’s investor relations website at https://ir.studiocity-macau.com/annual-reports. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests can be made through the Information Request section on the Company’s investor relations website at https://ir.studiocity-macau.com/document-request. Safe Harbor Statement This press release contains...

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging1 agent for prostate cancer. Gozellix®, after radiolabeling with 68Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gozellix® is a novel product which provides a longer shelf life of up to six hours and an extended...

Indkaldelse til ordinær generalforsamling den 23. april 2025 er vedhæftet.Med venlig hilsen PARKEN Sport & Entertainment A/SLars Ypkendanz CFOAttachment08-2025 Indkaldelse til OGF 2025

In connection with Borregaard’s Annual General Meeting, Mr. Helge Aasen, Chair of the Board of Directors in Borregaard ASA, has been assigned voting rights based on proxies for 7,137,969 shares in Borregaard ASA. The proxies apply exclusively to the Annual General Meeting in Borregaard ASA on 10 April 2025. This means that Mr. Helge Aasen represents a total of 7,14 % of the outstanding shares in Borregaard ASA. Mr. Helge Aasen’s shareholding in Borregaard ASA is 4,500 shares. Borregaard ASASarpsborg, 21 March 2025 Contact: Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act.